OncologyTube

Traditionally, tumor grade has long been a marker for breast cancer prognosis, but genomic insights are changing the standard of care.

Dr. Erin Cobain discusses how the 70-gene MammaPrint assay provides a more refined risk stratification, specifically identifying High Risk 2 tumors that may benefit most from anthracyclines and neoadjuvant immunotherapy.

Watch the full interview and see the latest updates on the SWOG S2206 clinical trial here: https://oncologytube.com/mammaprint-high-risk-immunotherapy-standard/

Is MammaPrint High Risk the New Standard for Guiding Immunotherapy? Dr. Erin Cobain explains how MammaPrint High-Risk genomic tests improve breast cancer prognosis and treatment.

Is PARP inhibitor + ARPI combination therapy the new first-line standard for BRCA-mutated metastatic prostate cancer?
In this timely interview from MOASC 2026, Dr. Charles B. Nguyen from City of Hope Orange County shares practical insights on:

Which patients benefit most (BRCA1/2 vs ATM)
Key data from PROpel, MAGNITUDE, TALAPRO-2 & AMPLITUDE
When to sequence PARP inhibitors
Genetic testing recommendations
Important toxicities to manage

Watch the full expert interview and read the detailed companion article:
👉 https://oncologytube.com/parp-inhibitors-prostate-cancer-moasc-2026-charles-nguyen/
What are your thoughts on moving PARP inhibitors earlier in the treatment paradigm? Drop a comment below!

When to Use PARP Inhibitors in Prostate Cancer as First-Line Therapy? When to start PARP inhibitors in prostate cancer with ARPI for BRCA-mutated cases? Dr. Charles Nguyen shares MOASC 2026 insights.